Advertisement
UK markets closed
  • NIKKEI 225

    38,274.05
    -131.61 (-0.34%)
     
  • HANG SENG

    17,763.03
    +16.12 (+0.09%)
     
  • CRUDE OIL

    79.13
    +0.13 (+0.16%)
     
  • GOLD FUTURES

    2,330.20
    +27.30 (+1.19%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • Bitcoin GBP

    46,216.77
    -1,843.20 (-3.84%)
     
  • CMC Crypto 200

    1,202.07
    -136.99 (-10.23%)
     
  • NASDAQ Composite

    15,605.48
    -52.34 (-0.33%)
     
  • UK FTSE All Share

    4,418.60
    -11.65 (-0.26%)
     

A NantHealth, Inc. (NASDAQ:NH) insider increased their holdings last year

Looking at NantHealth, Inc.'s (NASDAQ:NH ) insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.

Although we don't think shareholders should simply follow insider transactions, logic dictates you should pay some attention to whether insiders are buying or selling shares.

View our latest analysis for NantHealth

The Last 12 Months Of Insider Transactions At NantHealth

The Founder Patrick Soon-Shiong made the biggest insider purchase in the last 12 months. That single transaction was for US$5.0m worth of shares at a price of US$2.96 each. That means that even when the share price was higher than US$1.72 (the recent price), an insider wanted to purchase shares. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. As a general rule, we feel more positive about a stock when an insider has bought shares at above current prices, because that suggests they viewed the stock as good value, even at a higher price. The only individual insider to buy over the last year was Patrick Soon-Shiong.

ADVERTISEMENT

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From our data, it seems that NantHealth insiders own 3.2% of the company, worth about US$6.2m. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. We do generally prefer see higher levels of insider ownership.

So What Does This Data Suggest About NantHealth Insiders?

The fact that there have been no NantHealth insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. The transactions are fine but it'd be more encouraging if NantHealth insiders bought more shares in the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for NantHealth (of which 1 makes us a bit uncomfortable!) you should know about.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.